MindMed Announces First Patient Dosed in Phase 3 Voyage …
2 天之前 · MindMed’s Phase 2b study, MMED008, met its primary and key secondary endpoints and demonstrated rapid, clinically meaningful, and statistically significant improvements on the Hamilton Anxiety Rating Scale (HAM-A) at Week 4 and Week 12, with a 65% clinical response rate and 48% clinical remission rate sustained to Week 12 in the MM120 100 µg ...
MindMed Announces First Patient Dosed in Phase 3 Voyage
2 天之前 · MindMed’s Phase 2b study, MMED008, met its primary and key secondary endpoints and demonstrated rapid, clinically meaningful, and statistically significant improvements on the Hamilton Anxiety ...
Mind Med: First patient dosed in Voyage study of LSD in …
2 天之前 · Mind Medicine or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate LSD or the treatment of ...
MindMed Announces First Patient Dosed in Phase 3 Voyage …
2 天之前 · NEW YORK, December 16, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat ...
MindMed Receives FDA Breakthrough Therapy Designation and …
2024年3月7日 · NEW YORK-- (BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for t...
Mind Medicine (MindMed) Inc. (MNMD) Latest Stock News
Get the latest Mind Medicine (MindMed) Inc. (MNMD) stock news and headlines to help you in your trading and investing decisions.
News & Events :: Mind Medicine (MindMed) Inc. (MNMD)
2024年12月5日 · MindMed ACNP Congress 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
MindMed Receives FDA Breakthrough Therapy Designation and …
NEW YORK, March 07, 2024 -- (BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company...
MindMed Collaborators Announce Positive Topline Data from …
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that Prof. Matthias Liechti and Dr. Felix Mueller, MindMed collaborators at University Hospital Basel ...
MindMed Announces First Patient Dosed in Phase 3 Voyage …
2 天之前 · Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD.